Summary In an experimental setting, 4'-deoxydoxorubicin (4'-deoxy-DX) shows minimal cardiotoxicity as well as the marked antitumoral activity shown by doxorubicin, its parent compound. In this experimental study, the haematologic toxicity of the new anthracycline was investigated by haematopoietic precursor cell (HPC) assays using in vivo (colony-forming units -spleen, CFUS) and in vitro (CFU,-culture) methods with (C57B1 x C3H)F1 mice. Dose-survival curves and time response of HPC in situ following 4'-deoxy-DX administration were determined. In the time-related experiments, the effects of a single dose, an intermittent treatment (Days 0, 2, and 5) and a prolonged biweekly administration were studied. All dose-survival curves were exponential, with statistically significant differences between the effects on the various cell classes. CFUC appeared more sensitive than CFU,. In time-related experiments, 4'-deoxy-DX toxicity for HPC seemed to be relatively mild. However, CFU, sensitivity was again high in comparison with other populations assayed. In long-term administration, the 4-deoxy-DX effects on the haematopoietic system were also rather slight.
Modifications of the chemical structure of DX may significantly alter antitumour activity and toxicity of the molecule.
Research along these lines has produced some interesting derivatives of DX that have increased therapeutic indices and therefore could have a future in clinical application (Bonfante et al., 1979) . Of particular interest are compounds derived from modifications at position 4' of the anthracycline ring. Among these, 4'-deoxy-DX in an experimental setting has shown minimal or zero cardiotoxicity while maintaining the marked antitumoral activity of the parent compound (Casazza et al., 1980; Giuliani & Kaplan, 1980; Casazza et al., 1982) . In a human tumour stem cell assay, 4'-deoxy-DX had the greatest in vitro potency among 10 simultaneously tested anthracyclines (Salmon et al., 1981) . The cytotoxic effects of 4'-deoxy-DX have been studied in mice on various experimental tumours (L1210 leukaemia, P388 leukaemia, Gross leukaemia, solid 180 sarcoma, MS2 tumour, and early mammary carcinoma). The new drug was generally 2-3 times as potent and about twice as toxic as DX. However, its cardiac toxicity was much lower than that of DX, or even totally absent at low dosages. Since these data were very encouraging we decided to evaluate the toxic effects of 4'-deoxy-DX on the haematopoietic system, which could be the main dose-limiting factor of the new compound.
Accordingly we assayed the in situ dose and time response of HPC in mice treated with single or repeated doses of 4'-deoxy-DX. The general approach to this investigation was similar to that used in our previous studies on haematologic toxicity of other anthracycline derivatives (Muzzulini et al., 1981; Massa et al., 1982; Sobrero et al., 1982) .
Materials and methods

Mice
All experiments were performed on 2-3 month old (C57B1 x C3H)F1 mice. Irradiation of recipient mice was performed with a Theratron Junior cobalt 60 apparatus (0.8 Gy min-1; total dose delivered, 9 Gy). Drug 4'-deoxy-DX (laboratory code IMI 58 batch 2634/50), supplied by Farmitalia Carlo Erba (Milan, Italy) in the form of a red powder, was stored in the dark in a desiccator at 4°C and drug solutions were freshly prepared immediately before use.
The synthesis, structure, biologic and pharmacologic activities of the compound have been reported in several publications (Arcamone et al., 1976; Plumbridge & Brown, 1979; Casazza et al., 1980; Giuliani & Kaplan, 1980; Arcamone, 1981; Giuliani et al., 1981) .
For use, the drug was dissolved in saline solution and injected into the tail vein. 
Experimental design
Experiment A: Dose-survival curves of in vivo HPC in mice treated with 4'-deoxy-DX. The aim of this experiment was to assess the shape and the slope of in vivo dose-survival curves of haematopoietic cells and HPC, which allowed a comparison between the drug sensitivities of the various populations. In a preliminary study, the lethal effects of 4'deoxy-DX were studied in mice given different single doses of the drug. The animals were kept under observation for 31 days. On the basis of the mortality data, an LD50 of 3.02mgkg-1 body wt was calculated. In mice treated with 1.53mg kg-1 body wt, the survival was 100%, whereas none of the mice treated with 4.25mg kg-1 body wt survived. The dose range for experiment A was selected on the basis of these data. Five groups of 5 normal mice each received a single i.v. injection of 4'-deoxy-DX at various dose levels, i.e., 1.52, 1.81, 2.15, 2.55, 3.02, 3.58, and 4.25mgkg-1 body wt.
Twenty-four hours after i.v. injection, VPRC, total leukocyte count, and the number of reticulocytes per 100 RBC in orbital sinus blood were determined. The mice were then killed by cervical dislocation, femurs were removed, and bone marrow cellularity and HPC content were determined (see below). Haematological methods Peripheral blood cell counts, bone marrow collection, and preparation of single cell suspensions were performed by the usual techniques (Dacie & Lewis, 1975) . HPC were assayed as CFU5 by the transplant method of Till & McCulloch (1961) and as CFUC by the in vitro method of Bradley and Metcalf (1966) . Technical details have been reported in previous publications Sobrero et al., 1982) .
Statistical methods
To prevent possible day-to-day variations in the assays, single data points obtained in treated mice and in controls were determined on the same day. In the figures, the contents of CFUS and CFUC per femur were normalized to those found in salinetreated controls. The linear regressions between drug doses and survival fractions were fitted by the least squares method, and linear regression coefficients (r) and their significance were calculated. On the dose-survival curves, D37s were calculated on the basis of the equation y=a+bx (Bliss, 1970 For each experimental point: vertical bars, means + s.e. The r's: CFUsr= -0.97 (P<0.0l); CFU,r= -0.99 (P < 0.0l); bone marrow cellularity r = -0.99 (P < 0.0l). The suspension of bone marrow ofmice were pooled, and a cell count was made on the pool, thus preventing statistical evaluation of bone marrow cellularity differences. The suspension of bone marrow of mice were pooled, and a cell count was made on the pool, thus preventing statistical evaluation of bone marrow cellularity differences. a very marked decrease (to 4%), and of CFUS and CFUC, which fell to <30%. Whereas bone marrow cellularity and bone marrow CFU, content eventually recovered, reaching normal or near normal values by days 11-13, the CFUC recovery appeared slow and did not reach normal values. In the last 5 days of the observation period, there was a marked secondary decline in bone marrow cellularity levels, which at the end of the experiment were still around the low value of 20%. Overall, this schedule of administration of 4'-deoxy-DX appeared to have a greater effect on the bone marrow cells and HPC than on the peripheral blood cells. In comparison with the single dose administration, it delayed recovery for another [5] [6] [7] days. Also in this experiment the behaviour of CFUC was peculiar in that it showed a relatively inefficient recovery and a secondary decline. As in experiment B, the decline occurred too late for it to be caused by a direct toxic effect of the drug. bone marrow CFUC declined during the treatment period and thereafter recovered slowly, reaching normal values at week 17 (WBC) or remaining at a level well below normal (CFUC). Bone marrow cellularity dropped during the first 2 weeks of treatment, increased during the free interval, and then slowly recovered. There was a slight, slow decrease in bone marrow CFUS content for 6 weeks and then a steady slow recovery to the normal level. With this schedule of prolonged treatment, 4'-deoxy-DX did not appear to be particularly toxic for the haematopoietic system at a low dosage and only mildly toxic at the higher one. The haematopoietic system was able to fully recover after 5 weeks of exposure to the drug. The main toxic effect of 4'-deoxy-DX appeared to be on the granulopoietic lineage.
Discussion
To evaluate the myelotoxic activity of a drug, the assay of haematopoietic progenitor cell populations appears to be a very valuable test (Marsh, 1976; Lohrmann & Schreml, 1982) . As can be seen from previous research Sobrero et al., 1982) , although there are no great differences between the effects of different antitumoral drugs on peripheral blood cells and bone marrow cellularity, the differences may become evident when HPC are evaluated. Simple negative exponential dose-exposure curves were obtained by assaying the in vivo effect of 4'-deoxy-DX on bone marrow progenitor cells of mice 24h after administration of the drug. They showed that 4'-deoxy-DX causes a dose-related reduction in bone marrow HPC, and that it acts on all phases of the cell cycle. An important feature of the curve is the existence of a "shoulder" portion, i.e. the early nonexponential tract, which is probably an expression of the capacity of HPC to repair damage induced by low doses of the drug. These results are similar in pattern to those reported for other anthracyclines (Razek et al., 1972; Alberts & Van Daalen, 1976; Blackett et al., 1978; Buick et al., 1979; Huybrechts et al., 1979; Marsh, 1979; Muzzulini et al., 1981; Massa et al., 1982; Sobrero et al., 1982) .
There are some statistically significant differences between the effects of the new anthracycline on the various cell classes assayed. Progenitor cells committed to myeloid differentiation (CFUC), which 2.00- (Page et al., 1983) . However, in an experiment with 4'-epi-DX with a longer observation time, the secondary decline was eventually followed by a return to normal . One may speculate that this is related to the derangement of feedback mechanisms that control population size, which may occur in the case of depletion of bone marrow reserves.
Dose-response curves similar to those here reported for 4'-deoxy-DX may be obtained by plotting equal fractions and multiples of the LD50 of DX, 4'-epi-DX and 4'-demethoxydaunorubicin against their effects on mice bone marrow HPC Sobrero et al., 1982) . In comparison with the parent drug DX, at an equitoxic dose (LD50), both drugs exert a similar toxic effect on bone marrow cellularity and on peripheral blood cells. However, the reduction in CFU5 and CFUC is higher in DX-treated than in 4'-deoxy-DX-treated mice (respectively 20% survival versus 40%, and 16% versus 24%). Thus the new derivative, which is three times more potent than DX as far as antitumoral activity and general and haematologic toxicity are concerned, seems to have a rather low toxicity for HPC. From this point of view, its therapeutic index is better than that of the parent drug, although not as good as the therapeutic index concerning cardiotoxicity (Casazza et al., 1980) .
In time-survival experiments, the haematopoietic system shows fair resilience to the toxic effect of 4'-deoxy-DX. Following a single highly toxic dose of the drug or repeated administration of smaller doses, the pattern differs mainly as regards the decline and recovery times. However, in both cases recovery is complete except for the aforementioned secondary reduction in CFUC. Considering that in both experiments the dose injected was conspicuous from the point of view of general toxicity, haematologic toxicity and toxicity for HPC in particular seem to be relatively mild compared to the effect of other anthracyclines in similar experimental conditions. The administration of a small dose of the drug for several weeks once more brings to light the higher sensitivity of CFUC, because this population together with its derivative, WBC, is the only one depleted. Pluripotent stem cells appear completely spared. With a much higher dose, bone marrow cells and progenitors and peripheral blood cells are all affected to different degrees. On the whole, 4'-deoxy-DX appears to be a promising drug also from the point of view of haematologic toxicity. At doses that have the same antitumoral activity, 4'-deoxy-DX appears less toxic or no more toxic than DX. Therefore, its lower cardiotoxicity seems to be fully exploitable. In repeated and long-term administration, its toxic effect on HPC seems to be rather slight.
Further research is needed to ascertain whether this finding means that the new drug causes less residual haematopoietic damage.
